Business Description
Altamira Therapeutics Ltd
NAICS : 541714
SIC : 2834
ISIN : CH0408330303
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.15 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 71.2 | |||||
3-Year EPS without NRI Growth Rate | 65.5 | |||||
3-Year FCF Growth Rate | 63 | |||||
3-Year Book Growth Rate | -80.3 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.22 | |||||
9-Day RSI | 48.26 | |||||
14-Day RSI | 46.26 | |||||
6-1 Month Momentum % | -31.94 | |||||
12-1 Month Momentum % | -87.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 239.21 | |||||
Days Payable | 4009.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -272.7 | |||||
Shareholder Yield % | -59.15 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 6000 | |||||
Operating Margin % | 165775 | |||||
Net Margin % | 105650 | |||||
FCF Margin % | 323925 | |||||
ROA % | -56.21 | |||||
ROIC % | -73.76 | |||||
ROC (Joel Greenblatt) % | -2090.43 | |||||
ROCE % | -1206.39 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.14 | |||||
PB Ratio | 0.31 | |||||
Price-to-Tangible-Book | 0.78 | |||||
EV-to-EBIT | -0.42 | |||||
EV-to-EBITDA | -0.43 | |||||
EV-to-Revenue | -738.5 | |||||
EV-to-FCF | -0.22 | |||||
Earnings Yield (Greenblatt) % | -238.1 | |||||
FCF Yield % | -368.41 |